Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017



Rating:

Share or cite this content

Citations should be made in the following way:
Cormac McCarthy, John J. Brewington, Beth Harkness, John P. Clancy, Bruce C. Trapnell. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis. Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017

Member's Comments

No comment yet.

Related content which might interest you: Health-economic aspects of cystic fibrosis screening and therapy Source: Eur Respir Monogr 2014; 64: 304-319 Year: 2014 Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021 Year: 2021 New cystic fibrosis therapy targets Source: Research Seminar 2014 - Protein quality control in lung disease Year: 2014 Genotype-specific small-molecule therapy for cystic fibrosis Source: Breathe 2013; 9: 176-186 Year: 2013 Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Genotype specific therapies for cystic fibrosis Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies Year: 2004 Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019 Personalised medicine for cystic fibrosis: treating the basic defect Source: Eur Respir Rev 2013; 22: 3-5 Year: 2013 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Pathophysiology of CF and CFTR directed therapies Source: ERS course 2015 Year: 2015 Exercise testing in paediatric lung tranplant candidates with cystic fibrosis Source: Annual Congress 2010 - Pre-operative evaluation and post-operative problems after lung transplantation Year: 2010 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020